Cherwell SAS Microbial Air Sampling Secures User Satisfacti?on
Cherwell Laboratories, specialists in products for process validation and environmental monitoring, has affirmed its commitment to customer satisfaction and ISO9001:2008 Quality Management. This follows the recent completion of a user survey for its SAS microbial air monitoring equipment and calibration service. Cherwell’s customer satisfaction levels were rated high in all areas, with product knowledge and reliability ranking highest.
The SAS air sampler range includes a wide selection of portable hand held units, as well as the SAS Pinocchio compressed air sampling device and isolator specific units, all providing benefits for particular environmental monitoring purposes. SAS air sampling units use the multi-point impaction (single stage sieve) sampling technique to sample air at a fixed rate onto the agar surface of a standard contact plate or petri dish.
As part of its regular customer survey programme, Cherwell’s SAS customers were asked to rate the Company, its personnel, products and service across a broad range of areas. These included: product knowledge; SAS sampler reliability; accuracy and turnaround times for Service and Calibration services; and even the courtesy and manner of the courier service used for this. The majority of customers responding gave positive feedback in all areas, with Cherwell’s knowledge and product reliability ranking highest.
One happy customer also specifically observed that Cherwell’s Sales Administrator, Helen Deeley, ”…gains top marks from me for delivering all quotes promptly. She is very quick to reply and polite and I have always been very impressed by her. She is a real diamond and I do deal with a lot of other companies for getting quotes — Cherwell is the best!”
“Our Quality Management System enables continual improvement in the service we provide our customers and we regularly seek their feedback,” said Andrew Barrow, Sales Manager, Cherwell Laboratories. “We are extremely pleased with the positive response from our SAS air sampler customers and it inspires us to continue improving our high standards in product and service.”
Related News
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance